Wells Fargo
CTXR icon

Wells Fargo’s Citius Pharmaceuticals CTXR Stock Holding History

Wells Fargo’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40
Closed -$31 – 7234
2025
Q4 		$31 Hold
40
– – ﹤0.01% 6632
2025
Q3 		$50 Buy
+40
New +$56 ﹤0.01% 6485
2024
Q3 		– Sell
-160
Closed -$2.33K – 6942
2024
Q2 		$2.33K Sell
160
-1,874
-92% -$33.6K ﹤0.01% 5991
2024
Q1 		$45.6K Buy
2,034
+379
+23% +$6.92K ﹤0.01% 5296
2023
Q4 		$31.3K Buy
1,655
+298
+22% +$5.65K ﹤0.01% 5455
2023
Q3 		$23.2K Sell
1,357
-702
-34% -$16.7K ﹤0.01% 5538
2023
Q2 		$61.8K Buy
2,059
+1,862
+945% +$61.3K ﹤0.01% 5322
2023
Q1 		$5.77K Hold
197
– – ﹤0.01% 6016
2022
Q4 		$3.88K Buy
197
+1
+0.5% +$27 ﹤0.01% 5833
2022
Q3 		$6K Hold
196
– – ﹤0.01% 5847
2022
Q2 		$5K Sell
196
-993
-84% -$27.2K ﹤0.01% 5997
2022
Q1 		$53K Sell
1,189
-1,497
-56% -$59.1K ﹤0.01% 5624
2021
Q4 		$103K Sell
2,686
-23,258
-90% -$1.06M ﹤0.01% 5615
2021
Q3 		$1.32M Buy
25,944
+25,762
+14,155% +$1.29M ﹤0.01% 4013
2021
Q2 		$15K Buy
182
+73
+67% +$4.39K ﹤0.01% 5999
2021
Q1 		$5K Buy
109
+18
+20% +$717 ﹤0.01% 6491
2020
Q4 		$2K Buy
91
+1
+1% +$26 ﹤0.01% 6263
2020
Q3 		$2K Buy
90
+5
+6% +$141 ﹤0.01% 6128
2020
Q2 		$2K Sell
85
-658
-89% -$14.4K ﹤0.01% 6089
2020
Q1 		$11K Buy
743
+663
+829% +$14K ﹤0.01% 5728
2019
Q4 		$2K Hold
80
– – ﹤0.01% 6163
2019
Q3 		$2K Hold
80
– – ﹤0.01% 6188
2019
Q2 		$2K Hold
80
– – ﹤0.01% 6162
2019
Q1 		$3K Buy
+80
New +$2.35K ﹤0.01% 5801

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Wells Fargo's CTXR Position: Q1 2026 in Review

Wells Fargo sold out of Citius Pharmaceuticals (CTXR) in Q1 2026, closing a stake of 40 shares — an estimated $31 sold.

Wells Fargo first reported a position in CTXR in Q1 2019 and held it in 24 quarters. The position peaked at $1.32M in Q3 2021. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

  • Wells Fargo reported no remaining Citius Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Wells Fargo sold 40 Citius Pharmaceuticals shares in Q1 2026, an estimated $31.
  • Wells Fargo first reported a position in Citius Pharmaceuticals in Q1 2019 and held it in 24 quarters.
  • Wells Fargo's Citius Pharmaceuticals position peaked at $1.32M in Q3 2021.
  • 38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.